Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Accounts Payables (2017 - 2026)

Denali Therapeutics has reported Accounts Payables over the past 9 years, most recently at $3.3 million for Q4 2025.

  • Quarterly Accounts Payables fell 70.1% to $3.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.3 million through Dec 2025, down 70.1% year-over-year, with the annual reading at $3.3 million for FY2025, 70.1% down from the prior year.
  • Accounts Payables was $3.3 million for Q4 2025 at Denali Therapeutics, down from $6.7 million in the prior quarter.
  • Over five years, Accounts Payables peaked at $13.9 million in Q2 2024 and troughed at $1.2 million in Q3 2023.
  • The 5-year median for Accounts Payables is $6.9 million (2023), against an average of $6.6 million.
  • Year-over-year, Accounts Payables tumbled 84.32% in 2023 and then soared 711.68% in 2024.
  • A 5-year view of Accounts Payables shows it stood at $4.8 million in 2021, then plummeted by 41.62% to $2.8 million in 2022, then skyrocketed by 239.89% to $9.5 million in 2023, then grew by 17.44% to $11.1 million in 2024, then tumbled by 70.1% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Accounts Payables are $3.3 million (Q4 2025), $6.7 million (Q3 2025), and $10.8 million (Q2 2025).